Healthequity (HQY) Price Target Raised to $105.00
A number of other equities research analysts also recently commented on the company. Zacks Investment Research raised Healthequity from a sell rating to a hold rating in a research report on Friday, July 20th. KeyCorp lifted their target price on Healthequity from $82.00 to $90.00 and gave the company a buy rating in a report on Thursday, July 19th. Cantor Fitzgerald reiterated a hold rating and issued a $68.00 target price (up previously from $65.00) on shares of Healthequity in a report on Monday, June 4th. Bank of America started coverage on Healthequity in a report on Wednesday, May 23rd. They issued a buy rating and a $83.00 target price on the stock. Finally, SunTrust Banks lifted their target price on Healthequity to $105.00 and gave the company a buy rating in a report on Wednesday, September 5th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Healthequity currently has an average rating of Buy and a consensus price target of $93.08.
Shares of NASDAQ:HQY opened at $94.31 on Monday. The firm has a market capitalization of $5.86 billion, a PE ratio of 174.65, a price-to-earnings-growth ratio of 3.32 and a beta of 1.47. Healthequity has a 52 week low of $42.92 and a 52 week high of $97.94.
In other Healthequity news, VP Darcy G. Mott sold 4,000 shares of the business’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $86.37, for a total transaction of $345,480.00. Following the transaction, the vice president now owns 99,200 shares in the company, valued at $8,567,904. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Evelyn S. Dilsaver sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $77.46, for a total value of $1,161,900.00. Following the transaction, the director now owns 28,193 shares in the company, valued at approximately $2,183,829.78. The disclosure for this sale can be found here. Insiders sold 41,500 shares of company stock worth $3,312,481 in the last quarter. 4.00% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Citigroup Inc. lifted its stake in shares of Healthequity by 414.4% during the first quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock worth $160,000 after purchasing an additional 2,126 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Healthequity by 5,212.2% during the second quarter. Advisors Asset Management Inc. now owns 72,086 shares of the company’s stock worth $160,000 after purchasing an additional 70,729 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Healthequity during the second quarter worth about $179,000. Cim LLC acquired a new position in shares of Healthequity during the second quarter worth about $204,000. Finally, S&CO Inc. acquired a new position in shares of Healthequity during the second quarter worth about $204,000. Institutional investors own 96.99% of the company’s stock.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Article: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.